you are viewing a single comment's thread.
Leiden was a board member starting in 1999 and became an official employee (i.e., COO) in 2000.So, he was there before the BASF deal. The BASF deal was Miles' idea. Miles put his name in the hat and bumped the Knoll offer to beat out a number of other pharmas. The bad R&D pharma pipeline was a cause of his predecessor, the bean counter, Duane, plus Abbott has never been regarded as a innovative drug developer. The only drugs that came through the Abbott Discovery branch since 1970 were Hytrin, Survanta, Norvir, and Kaletra. All the others were inlicensed or acquired.